BofA/Merrill Lynch Downgrades Abbvie (ABBV) to Neutral; Valuation Reflects Expectations
Tweet Send to a Friend
BofA/Merrill Lynch downgraded Abbvie (NYSE: ABBV) from Buy to Neutral with a price target of $70.00 (from $66.00), saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
